Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103). [electronic resource]
Producer: 20191112Description: 97-105 p. digitalISSN:- 1432-0843
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Benzofurans -- administration & dosage
- Carboplatin -- administration & dosage
- Cystadenocarcinoma, Serous -- drug therapy
- Deoxycytidine -- administration & dosage
- Endometrial Neoplasms -- drug therapy
- Female
- Follow-Up Studies
- Humans
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Organophosphates -- administration & dosage
- Ovarian Neoplasms -- drug therapy
- Prognosis
- Survival Rate
- Gemcitabine
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.